The All-Ireland Infectious Diseases cohort study (AIID Cohort) is enrolling patients at a
number of Irish Hospitals with infectious diseases, including Covid-19. The AIID Cohort
is a multicentre, prospective, longitudinal, observational cohort that enrols consecutive
adult subjects (>18 years old) attending hospitals services for management of infections.

Subjects provide consent for use of routine clinical and laboratory data for research.
All data is collected by a combination of retrospective medical note review and
extraction of data from electronic health records. At a minimum, the following data items
are to be collected at enrolment and subsequent clinic visits:

1. Demography and basic information (e.g. date of birth, gender, country of origin,
ethnicity, anthropometric assessments, and reasons for the attendance, date or year
for disease diagnosis and transmission risk.

2. Laboratory data: Relevant routine virological (including genotyping) and
immunological data for characterisation of the HIV infection, TB, hepatitis C,
COVID-19 and other relevant co-infections will also be collected as well as other
relevant clinical routine data on tolerability and safety (i.e., renal, liver,
lipids)

3. Medical treatment: All medications, including start-and stop dates and reason for
discontinuation, adherence. Concomitant medical treatment related to co-infections
and co-morbidities.

4. Clinical events: hospitalisation, diseases specific relevant active and previous
diagnosis (e.g., AIDS and non-AIDS events, including comorbidities).

In addition, subjects are asked to provide biological samples for up to five occasions
every six months for bio-banking for host profiling and pathogen bio-repository. To
provide flexibility for participants around requirements for fasting or scheduling,
participants may be asked to attend to provide samples for biobanking outside of routine
scheduled clinic visits. These stored samples provide the opportunity for future research
studies investigating host factors associated with the response to infection.

The AIID Cohort is approved by local institutional review boards and all participants
provide written, informed consent. Data and samples within the AIID Cohort are accessed
through standardised Data Access Guidelines and all approved Data Access Requests are
approved by the local Ethics Committee.